Celia Schiffer to CRISPR-Cas Systems
This is a "connection" page, showing publications Celia Schiffer has written about CRISPR-Cas Systems.
Connection Strength
0.927
-
Lee JM, Zeng J, Liu P, Nguyen MA, Suchenski Loustaunau D, Bauer DE, Kurt Yilmaz N, Wolfe SA, Schiffer CA. Direct delivery of Cas-embedded cytosine base editors as ribonucleoprotein complexes for efficient and accurate editing of clinically relevant targets. Nucleic Acids Res. 2025 Jan 07; 53(1).
Score: 0.694
-
Cai EP, Ishikawa Y, Zhang W, Leite NC, Li J, Hou S, Kiaf B, Hollister-Lock J, Yilmaz NK, Schiffer CA, Melton DA, Kissler S, Yi P. Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes. Nat Metab. 2020 09; 2(9):934-945.
Score: 0.127
-
Ma L, Boucher JI, Paulsen J, Matuszewski S, Eide CA, Ou J, Eickelberg G, Press RD, Zhu LJ, Druker BJ, Branford S, Wolfe SA, Jensen JD, Schiffer CA, Green MR, Bolon DN. CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy. Proc Natl Acad Sci U S A. 2017 10 31; 114(44):11751-11756.
Score: 0.105